FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns a pharmaceutical composition for local application on the surface of an epithelium barrier, containing a soluble, antigen-binding polypeptide, and a pharmaceutically acceptable carrier, a diluent, or an excipient. The above polypeptide is able to permeate through at least one or more epithelium barriers for less than 8 hours in the absence of a permeation enhancer. The antigen-binding polypeptide as a part of the above pharmaceutical composition represents a single-chain antibody containing the sequence SEQ.ID: 12, SEQ.ID: 13, SEQ.ID: 18, SEQ.ID: 19, SEQ.ID: 20 or SEQ.ID: 21.
EFFECT: using the invention has many advantages as compared to injections and other modes of administration: ease of delivery, as well as reducing or eliminating problems of the patient's compliance with the treatment regimen and sequence accompanying injection delivery.
21 cl, 28 dwg, 3 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
ScFv-ANTIBODIES, WHICH PASS THROUGH EPITHELIAL AND/OR ENDOTHELIAL LAYERS | 2007 |
|
RU2438708C2 |
STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2018 |
|
RU2678120C1 |
STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFΑ | 2018 |
|
RU2704838C1 |
METHODS AND COMPOSITIONS FOR IMPROVED DELIVERY OF MACROMOLECULES | 2009 |
|
RU2522245C2 |
STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2009 |
|
RU2653753C1 |
STABLE AND SOLUBLE ANTIBODIES | 2011 |
|
RU2558298C2 |
STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2009 |
|
RU2567100C2 |
OPTIMISING SOLUBILITY OF IMMUNOBINDERS | 2009 |
|
RU2514658C2 |
OPTIMISING SOLUBILITY OF IMMUNOBINDERS | 2014 |
|
RU2653441C2 |
FUNCTIONALISED POLYPEPTIDES | 2009 |
|
RU2582244C2 |
Authors
Dates
2015-10-20—Published
2011-06-24—Filed